M A van der Aa
Overview
Explore the profile of M A van der Aa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Incomplete surgical staging in clinical early-stage ovarian cancer: guidelines versus daily practice
Laven P, Beltman J, Bense J, van der Aa M, Van Gorp T, Vos M, et al.
Surg Open Sci
. 2021 Nov;
7:6-11.
PMID: 34778737
Background: Incomplete surgical staging of patients with early-stage epithelial ovarian cancer (EOC) has been reported in up to 98% of cases, when based on the International Federation of Obstetrics and...
2.
Elzakkers J, van der Aa M, van Altena A, de Hullu J, Harmsen M
Gynecol Oncol
. 2019 Sep;
155(2):213-219.
PMID: 31477282
Objective: Optimizing the counselling of women ≤40years with epithelial ovarian cancer (EOC) by investigating the role of young age and tumour characteristics on overall survival (OS). Methods: A retrospective population-based...
3.
Timmermans M, Zwakman N, Sonke G, Van de Vijver K, Duk M, van der Aa M, et al.
Eur J Obstet Gynecol Reprod Biol
. 2019 Aug;
240:364-369.
PMID: 31400565
Objective: Despite being the most important prognostic factor for prolonged overall survival in epithelial ovarian cancer (EOC), the measurement of residual disease is hampered by its subjective character. Additional assessment...
4.
van der Hel O, Timmermans M, van Altena A, Kruitwagen R, Slangen B, Sonke G, et al.
Eur J Cancer
. 2019 Jul;
118:97-104.
PMID: 31326731
Introduction: About 5% of ovarian tumours have a non-epithelial histology, including germ cell tumours (GCTs), sex cord-stromal tumours (SCSTs) and sarcomas. Because these non-epithelial ovarian tumours are rare and population-based...
5.
Timmermans M, Sonke G, Slangen B, Baalbergen A, Bekkers R, Fons G, et al.
Eur J Surg Oncol
. 2019 Apr;
45(8):1425-1431.
PMID: 31027945
Introduction: The care for patients with epithelial ovarian cancer(EOC) is organised in eight different geographical regions in the Netherlands. This situation allows us to study differences in practice patterns and...
6.
van Baal J, Van de Vijver K, Algera M, van der Aa M, Sonke G, van Driel W, et al.
Gynecol Oncol
. 2019 Apr;
153(3):562-567.
PMID: 30948193
Objective: The benefit of adjuvant chemotherapy for FIGO stage I, high-grade serous ovarian cancer (HGSOC) after optimal staging is a matter of debate. We investigated the effect of adjuvant chemotherapy...
7.
Timmermans M, van der Hel O, Sonke G, Van de Vijver K, van der Aa M, Kruitwagen R
Gynecol Oncol
. 2019 Mar;
153(2):445-451.
PMID: 30826010
Introduction: The ability to minimize residual disease during primary cytoreductive surgery is the strongest predictor for improved overall survival in advanced ovarian cancer. But while the probability to achieve a...
8.
Timmermans M, Sonke G, Van de Vijver K, Ottevanger P, Nijman H, van der Aa M, et al.
Int J Gynecol Cancer
. 2019 Jan;
29(2):392-397.
PMID: 30665898
Background: Patients with ovarian cancer who are diagnosed with Federation of Gynecology and Obstetrics (FIGO) stage IV disease are a highly heterogeneous group with possible survival differences. The FIGO staging...
9.
Timmermans M, van der Aa M, Lalisang R, Witteveen P, Van de Vijver K, Kruitwagen R, et al.
Gynecol Oncol
. 2018 Jul;
150(3):446-450.
PMID: 30001834
Objective: Treatment for advanced epithelial ovarian cancer (EOC) consists of debulking surgery and (neo)adjuvant platinum-based chemotherapy. The aim of this study was to evaluate whether the time from surgery to...
10.
van der Linden M, Schuurman M, Bulten J, Massuger L, IntHout J, van der Aa M, et al.
Br J Dermatol
. 2018 Jun;
179(6):1315-1321.
PMID: 29923188
Background: Vulvar Paget disease (VPD) is extremely rare and thought to be associated with other malignancies. Objectives: To evaluate the risk of developing breast, intestinal and urological malignancies in patients...